Information Provided By: 
Fly News Breaks for April 5, 2016
VRX, PGNX
Apr 5, 2016 | 07:46 EDT
Jefferies analyst Gena Wang believes the approvability of Relistor in opioid-induced constipation is unchanged after the FDA pushed back the drug's action date. She sees a favorable risk/reward for shares of Progenics (PGN) ahead of the PDUFA date and keeps a Buy rating on the shares with a $9 price target. Wang points out that the FDA requested no new data from Progenics partner Valeant (VRX).
News For PGNX;VRX From the Last 2 Days
There are no results for your query PGNX;VRX
